{"id":10485,"date":"2025-03-03T09:25:17","date_gmt":"2025-03-03T08:25:17","guid":{"rendered":"https:\/\/ep-ad.org\/?p=10485"},"modified":"2025-10-21T10:59:43","modified_gmt":"2025-10-21T09:59:43","slug":"alzheimers-dementia-diagnosis-assessment-disease-monitoring","status":"publish","type":"post","link":"https:\/\/ep-ad.org\/index.php\/2025\/03\/03\/alzheimers-dementia-diagnosis-assessment-disease-monitoring\/","title":{"rendered":"Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring"},"content":{"rendered":"\n

“Accrual of Alzheimer’s disease pathology as a function of proximity to parental dementia onset”<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Authors:<\/strong> Elina T. Ziukelis, Elijah Mak, Craig Ritchie, John T. O’Brien, Dag Aarsland, for the European Prevention of Alzheimer’s Disease (EPAD) Consortium<\/p>\n\n\n\n

Abstract:<\/strong><\/p>\n\n\n\n

Introduction: Whether temporal proximity to parental onset of dementia (PPO) can be used to estimate timing of the preclinical stage of sporadic Alzheimer’s disease (AD) remains uncertain.<\/p>\n\n\n\n

Methods: We investigated cross-sectionally adults aged > 50 without dementia included in the European Prevention of Alzheimer’s Dementia (EPAD) study. PPO was tested as a predictor of quantitative levels of cerebrospinal fluid (CSF) \u03b2-amyloid (1-42) (A\u03b21-42) in those with a parental history of dementia (n<\/em> = 688) and of phosphorylated tau (p-tau) and EPAD neuropsychological examination (ENE) subscores in an amyloid positive subgroup (n<\/em> = 226). Possible interactions were explored.<\/p>\n\n\n\n

Results: Shorter PPO predicted lower CSF A\u03b21-42 level (\u03b2 = 9.357; T = 4.161; p<\/em> < 0.001), interacting with apolipoprotein E (APOE) -\ud835\udf004 carriage in a dose-dependent manner. Concomitant APOE-\ud835\udf002 carriage appeared to provide protection. PPO did not predict p-tau levels or cognitive performance.<\/p>\n\n\n\n

Discussion: PPO may provide a valid method of stratifying risk of early AD pathologic change in APOE-\ud835\udf004 carriers, with empirical and clinical applications.<\/p>\n\n\n\n

Highlights:<\/p>\n\n\n\n